Recruitment

Recruitment Status
Unknown status

Inclusion Criterias

Patients Either May or May Not Have a Prior Anthracycline Containing Regimen.
Adequate Renal Function (≤ Serum Creatinine 1.5 mg/dl or CCr ≥ 50 ml/Min)
No Prior History of Chemotherapy for Metastatic, Recurrent Breast Cancer
...
Patients Either May or May Not Have a Prior Anthracycline Containing Regimen.
Adequate Renal Function (≤ Serum Creatinine 1.5 mg/dl or CCr ≥ 50 ml/Min)
No Prior History of Chemotherapy for Metastatic, Recurrent Breast Cancer
Premenopausal or Postmenopausal Breast Cancer Patients With Measurable or Non-Measurable Lesions, Who Are Candidates for Chemotherapy
Prior Hormonal Therapy as a Treatment of Metastatic Disease is Allowed. But Antitumoral Hormonal Therapy Must be Terminated Prior to Enrollment(up to the Date of Randomization)
Patients May Have Received Prior Neoadjuvant or Adjuvant Taxane Regimen as Long as it Has Been 12 Months Since Completion of Regimen.
Life Expectancy ≥ 3 Months
Adequate Bone Marrow Function (≥ ANC 1,500/ul, ≥ Platelet 100,000/ul, ≥ Hemoglobin 9.0 g/dl)
Age over 18 Years
Histologically Confirmed Metastatic, or Recurrent Breast Cancer
Prior Radiation Therapy Allowed as Long as < 25% of the Bone Marrow Has Been Treated,and the Patients Must Have Recovered From the Acute Toxic Effects of the Treatment Prior to Study Enrollment.Prior Radiation to the Whole Pelvis is Not Allowed. Prior Radiotherapy Must be Completed 4 Weeks Before Study Entry.
Adequate Liver Function (≤ Serum Bilirubin 1.5 mg/dl, ≤ AST/ALT x 3 Upper Normal Limit)
ECOG Performance Status 0-2
Written Informed consent

Exclusion Criterias

HER-2 Overexpressing Breast Cancer and Concomitant Trastuzumab Treatment is Not Allowed
Peripheral Neuropathy ≥ Grade 2
Second Primary Malignancy(Except Cancer of Cervix or Skin or Other Malignancy Treated at Least 5 Years Previously With no Evidence of Recurrence)
...
HER-2 Overexpressing Breast Cancer and Concomitant Trastuzumab Treatment is Not Allowed
Peripheral Neuropathy ≥ Grade 2
Second Primary Malignancy(Except Cancer of Cervix or Skin or Other Malignancy Treated at Least 5 Years Previously With no Evidence of Recurrence)
Serious Uncontrolled Intercurrent Infections
Documented Parenchymal or Leptomeningeal Brain Metastasis
Serious Intercurrent Medical or Psychiatric Illness, Including Active Cardiac Disease
Prior Treatment With Gemcitabine Will Not be Allowed.
Pregnancy or Breast Feeding

Summary

Conditions
  • Gemcitabine
  • Maintenance Chemotherapy
  • Stage IIIB, IV, Recurrent, and Metastatic Breast Cancer
Design
  • Observational Model: Case-Control
  • Time Perspective: Prospective

Participation Requirements

Age
Between 18 years and 70 years
Gender
Only females

Inclusion Criterias

Patients Either May or May Not Have a Prior Anthracycline Containing Regimen.
Adequate Renal Function (≤ Serum Creatinine 1.5 mg/dl or CCr ≥ 50 ml/Min)
No Prior History of Chemotherapy for Metastatic, Recurrent Breast Cancer
...
Patients Either May or May Not Have a Prior Anthracycline Containing Regimen.
Adequate Renal Function (≤ Serum Creatinine 1.5 mg/dl or CCr ≥ 50 ml/Min)
No Prior History of Chemotherapy for Metastatic, Recurrent Breast Cancer
Premenopausal or Postmenopausal Breast Cancer Patients With Measurable or Non-Measurable Lesions, Who Are Candidates for Chemotherapy
Prior Hormonal Therapy as a Treatment of Metastatic Disease is Allowed. But Antitumoral Hormonal Therapy Must be Terminated Prior to Enrollment(up to the Date of Randomization)
Patients May Have Received Prior Neoadjuvant or Adjuvant Taxane Regimen as Long as it Has Been 12 Months Since Completion of Regimen.
Life Expectancy ≥ 3 Months
Adequate Bone Marrow Function (≥ ANC 1,500/ul, ≥ Platelet 100,000/ul, ≥ Hemoglobin 9.0 g/dl)
Age over 18 Years
Histologically Confirmed Metastatic, or Recurrent Breast Cancer
Prior Radiation Therapy Allowed as Long as < 25% of the Bone Marrow Has Been Treated,and the Patients Must Have Recovered From the Acute Toxic Effects of the Treatment Prior to Study Enrollment.Prior Radiation to the Whole Pelvis is Not Allowed. Prior Radiotherapy Must be Completed 4 Weeks Before Study Entry.
Adequate Liver Function (≤ Serum Bilirubin 1.5 mg/dl, ≤ AST/ALT x 3 Upper Normal Limit)
ECOG Performance Status 0-2
Written Informed consent

Exclusion Criterias

HER-2 Overexpressing Breast Cancer and Concomitant Trastuzumab Treatment is Not Allowed
Peripheral Neuropathy ≥ Grade 2
Second Primary Malignancy(Except Cancer of Cervix or Skin or Other Malignancy Treated at Least 5 Years Previously With no Evidence of Recurrence)
...
HER-2 Overexpressing Breast Cancer and Concomitant Trastuzumab Treatment is Not Allowed
Peripheral Neuropathy ≥ Grade 2
Second Primary Malignancy(Except Cancer of Cervix or Skin or Other Malignancy Treated at Least 5 Years Previously With no Evidence of Recurrence)
Serious Uncontrolled Intercurrent Infections
Documented Parenchymal or Leptomeningeal Brain Metastasis
Serious Intercurrent Medical or Psychiatric Illness, Including Active Cardiac Disease
Prior Treatment With Gemcitabine Will Not be Allowed.
Pregnancy or Breast Feeding

Locations

Xi'an, Shaanxi, 710032
Xi'an, Shaanxi, 710032

Tracking Information

NCT #
NCT02188693
Collaborators
Eli Lilly and Company
Investigators
Study Director: Li Nanlin, Ph.D Air Force Military Medical University, China